News Category
Onco-Innovations' LOI with Ifowonco could expand its immuno-oncology pipeline, potentially enhancing solid tumor treatments by combining DDR inhibitio...
Creative Biolabs expands its complement assay services, providing advanced tools for evaluating complement-targeted therapeutics and accelerating prec...
Quantum BioPharma's Lucid-MS offers a novel approach to treating multiple sclerosis by targeting myelin degradation and smoldering lesions, potentiall...
Silo Pharma's receipt of a Canadian patent allowance for SPC-15 strengthens its intellectual property position and advances its PTSD therapeutic towar...
Quantum BioPharma's Lucid-MS, a first-in-class therapy aimed at protecting myelin without immunosuppression, has received FDA clearance for phase 2 tr...
Regentis Biomaterials strengthens its IP portfolio and commercial-scale manufacturing capabilities for its GelrinC cartilage-repair product, advancing...
VERAXA Biotech's collaboration with Ardigen uses AI to optimize its oncology pipeline, potentially reducing development risks and reviving abandoned d...
VERAXA Biotech's collaboration with AI firm Ardigen aims to enhance its oncology pipeline by using artificial intelligence to identify optimal dual-ta...
The American Heart Association's 2026 Health Tech Competition seeks market-ready technologies to improve cardiovascular and brain health, with finalis...
Scientists have identified a protein on glioblastoma cells that could be targeted to make the cancer more vulnerable to existing treatments, offering ...
NanoViricides is set to begin a Phase II trial of NV-387 Oral Gummies for Ebola in the DRC, potentially offering a more accessible treatment option in...
Helus Pharma's appointment of seasoned executives from Intra-Cellular signals strategic preparation for commercialization of its novel serotonergic ag...
Cayenne Wellness Center hosts its 20th Annual Sickle Cell Disease Educational Summit, highlighting two decades of progress and ongoing challenges in s...
Helix BioPharma strengthens its leadership with Dr. Loeffler to advance L-DOS47 and LEUMUNA through pivotal clinical milestones, underscoring its comm...
Quantum BioPharma reports significant expense reductions and FDA approval for its Phase 2 trial of Lucid-MS in progressive multiple sclerosis, marking...
Regentis Biomaterials is progressing its cartilage repair product GelrinC through a pivotal US trial while simultaneously expanding commercial activit...
Alpha Cognition's 2Q26 results beat expectations with strong ZUNVEYL demand, but payer implementation remains low, indicating significant upside poten...
The Lung Cancer Foundation of America and the International Association for the Study of Lung Cancer have awarded $200,000 each to two early-career sc...
PX1 Research's domestic cGMP-certified peptides now pass a seven-stage testing protocol at 99%+ purity, offering batch-level COA documentation and sam...
A comprehensive review in World Journal of Pediatric Surgery synthesizes operative approaches for necrotizing enterocolitis, emphasizing bowel preserv...
Onco-Innovations is progressing its precision oncology candidate ONC010 through IND-enabling activities, positioning itself to address biomarker-selec...
Regentis Biomaterials advances its GelrinC hydrogel implant with European approval of a more efficient manufacturing process and progress in U.S. tria...
Researchers at the University of Manchester discovered that a rare subset of immune cells, previously overlooked, is crucial for initiating and mainta...
Quantum BioPharma's cost-cutting measures and FDA approval for its lead multiple sclerosis drug candidate mark a pivotal step toward clinical advancem...
Regentis Biomaterials is strategically advancing its cartilage repair product GelrinC through simultaneous US clinical trials and European commerciali...
Lantern Pharma reported Q2 2026 results highlighting progress in its AI-driven oncology pipeline and the establishment of Open Medicine AI as a separa...
Helus Pharma's completion of enrollment in its pivotal Phase 3 trial for HLP003 marks a significant step toward a potential new treatment for major de...
DM Clinical Research's 20th anniversary underscores its growth into a leading network of 35+ sites, 35,000 enrolled patients, and a commitment to pati...
NeOnc's NEO100 shows promising survival benefits in recurrent brain cancer, positioning the company for FDA alignment and a potential registrational p...
PX1 Research expands its dual-incretin peptide catalog with domestically manufactured Retatrutide and Tirzepatide, each batch verified for 99%+ purity...
Quantum BioPharma's Lucid-MS focuses on progression independent of relapse activity, a key driver of long-term disability in MS, marking a shift in tr...
As the Bundibugyo Ebola outbreak in the DRC escalates, GeoVax offers its MVA-based vaccine candidates and expertise to support global response efforts...
Amid looming tariffs on drug imports, global pharmaceutical companies are investing approximately $500 billion in US facilities, reshaping the industr...
Nutriband's CEO will showcase its AVERSA abuse-deterrent transdermal technology at a major industry summit, underscoring the company's role in address...
Quantum BioPharma's FDA clearance to advance Lucid-MS into Phase 2 trials marks a significant step toward a potential neuroprotective therapy for mult...
PX1 Research introduces a line of US-manufactured sublingual peptide strips for needle-free research, offering verified purity and a non-invasive alte...
PX1 Research now applies seven-stage HPLC purity verification and cGMP standards to all US-manufactured research peptides, ensuring 99%+ purity with b...
NanoViricides has received regulatory approval to begin a Phase II trial of its oral antiviral NV-387 for the Bundibugyo ebolavirus outbreak, potentia...
Research at the University of Virginia suggests focused ultrasound could improve brain tumor treatment, offering a less harmful alternative to convent...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn suppresses tumor growth in prostate and triple-negative breast can...
Quantum BioPharma's FDA approval to start Phase 2 trials for Lucid-MS, a neuroprotective candidate for multiple sclerosis, marks a significant step to...
Tonix Pharmaceuticals' Q2 2026 revenue jumped to $13.5 million driven by TONMYA sales, signaling successful commercial launch and promising pipeline d...
Tonix Pharmaceuticals' Q2 revenue surged to $13.5 million, propelled by TONMYA's commercial success, signaling a major milestone for the company and t...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, driven by TONMYA sales of $11 million, signaling strong market adoption and financial ...
A new narrative review provides a comprehensive framework for risk-adapted treatment of neuroblastoma, emphasizing the integration of clinical, biolog...
Regentis Biomaterials is progressing its GelrinC cartilage regeneration technology through clinical trials, FDA submission preparation, European comme...
Quantum BioPharma is advancing its two-pronged approach to neurological health with the investigational MS therapy Lucid-MS and the supplement unbuzzd...
Quantum BioPharma is advancing its two-pronged approach to neurological health, targeting multiple sclerosis with Lucid-MS and alcohol misuse with unb...
